Syngene International announced an extension of its partnership with Bristol Myers Squibb (BMS) through 2035, expanding integrated services. Q3 FY26 revenue from operations reached ₹917 Cr, while operating EBITDA margin was 23%. The company continued investing in new technologies and expanded advanced chemistry capabilities in Hyderabad. Syngene also earned recognition from TIME magazine for Sustainable Growth.
Strategic Partnership Extension
Syngene International has extended its long-standing partnership with Bristol Myers Squibb (BMS) to 2035. This extended agreement will broaden the scope of integrated services across the drug development lifecycle, including discovery, translational sciences, pharmaceutical development and manufacturing, and clinical trials.
Q3 FY26 Financial Performance
The company’s Q3 FY26 financial highlights include:
- Revenue from Operations: ₹917 Cr (down 3% year-over-year)
- Operating EBITDA margin: 23% (compared to 30% in Q3 FY25)
- Reported PAT before exceptional items: ₹73 Cr (down 44% year-over-year)
9M FY26 Financial Performance
The financial performance for the first nine months of FY26 shows:
- Revenue from Operations: ₹2,702 Cr (up 3% year-over-year)
- Operating EBITDA margin: 23% (compared to 27% in 9M FY25)
- Reported PAT before exceptional items: ₹227 Cr (down 22% year-over-year)
Investments and Expansions
Syngene continued its strategy of investing in new technologies, including AI, novel modalities, and advanced processes. The company commissioned a new commercial-scale facility for liquid-filled hard gelatin capsules and expanded its advanced chemistry capabilities at its Hyderabad site.
Recognition
Syngene earned the prestigious 5S Certification and was ranked amongst the “World’s Best Companies in Sustainable Growth” list 2026 by TIME magazine and Statista, ranking amongst the top three globally and #1 in India in the Pharma and Biotech category.
Source: BSE
